Karyopharm Therapeutics Inc. (KPTI) stock
KPTINasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPTIQ
$0.04−0.01 (-20.00%)
Close on Nov 9, 2026Market cap $1.16KP/E –Yield –
Karyopharm Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Karyopharm Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $120.97M, down 11.6% year over year. For fiscal 2025 it was $125.62M, down 12.3% from the year before. Over ten years it grew 2.5% a year on average. The highest annual figure on record is $161.37M in fiscal 2018.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $125.62M | -12.3% |
| FY2024 | Dec 31, 2024 | $143.23M | +3.2% |
| FY2023 | Dec 31, 2023 | $138.75M | -6.7% |
| FY2022 | Dec 31, 2022 | $148.66M | -7.6% |
| FY2021 | Dec 31, 2021 | $160.84M | +6.6% |
| FY2020 | Dec 31, 2020 | $150.81M | +23.3% |
| FY2019 | Dec 31, 2019 | $122.34M | -24.2% |
| FY2018 | Dec 31, 2018 | $161.37M | +50.4% |
| FY2017 | Dec 31, 2017 | $107.27M | +23.4% |
| FY2016 | Dec 31, 2016 | $86.94M | -11.1% |
| FY2015 | Dec 31, 2015 | $97.74M | +62.6% |
| FY2014 | Dec 31, 2014 | $60.13M | +111.3% |
| FY2013 | Dec 31, 2013 | $28.45M | +101.9% |
| FY2012 | Dec 31, 2012 | $14.10M | +63.5% |
| FY2011 | Dec 31, 2011 | $8.62M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $28.96M | -11.7% |
| Q1 FY2026 | Mar 31, 2026 | $33.80M | -2.4% |
| Q4 FY2025 | Dec 31, 2025 | $27.67M | -16.9% |
| Q3 FY2025 | Sep 30, 2025 | $30.54M | -15.5% |
| Q2 FY2025 | Jun 30, 2025 | $32.79M | -14.6% |
| Q1 FY2025 | Mar 31, 2025 | $34.62M | -2.3% |
| Q4 FY2024 | Dec 31, 2024 | $33.30M | -15.4% |
| Q3 FY2024 | Sep 30, 2024 | $36.13M | +1.6% |
| Q2 FY2024 | Jun 30, 2024 | $38.37M | +21.9% |
| Q1 FY2024 | Mar 31, 2024 | $35.43M | +9.5% |
| Q4 FY2023 | Dec 31, 2023 | $39.38M | +27.3% |
| Q3 FY2023 | Sep 30, 2023 | $35.55M | +13.4% |
| Q2 FY2023 | Jun 30, 2023 | $31.48M | -29.0% |
| Q1 FY2023 | Mar 31, 2023 | $32.34M | -23.1% |
| Q4 FY2022 | Dec 31, 2022 | $30.93M | -29.7% |
| Q3 FY2022 | Sep 30, 2022 | $31.36M | -31.5% |
| Q2 FY2022 | Jun 30, 2022 | $44.31M | +30.4% |
| Q1 FY2022 | Mar 31, 2022 | $42.06M | +13.5% |
| Q4 FY2021 | Dec 31, 2021 | $44.00M | +18.3% |
| Q3 FY2021 | Sep 30, 2021 | $45.81M | +23.7% |
| Q2 FY2021 | Jun 30, 2021 | $33.98M | -20.2% |
| Q1 FY2021 | Mar 31, 2021 | $37.05M | +9.0% |
| Q4 FY2020 | Dec 31, 2020 | $37.19M | +17.8% |
| Q3 FY2020 | Sep 30, 2020 | $37.04M | +41.0% |
| Q2 FY2020 | Jun 30, 2020 | $42.59M | +60.6% |
| Q1 FY2020 | Mar 31, 2020 | $34.00M | -10.5% |
| Q4 FY2019 | Dec 31, 2019 | $31.58M | -18.8% |
| Q3 FY2019 | Sep 30, 2019 | $26.27M | -27.9% |
| Q2 FY2019 | Jun 30, 2019 | $26.52M | -40.7% |
| Q1 FY2019 | Mar 31, 2019 | $37.97M | -8.1% |
| Q4 FY2018 | Dec 31, 2018 | $38.89M | +11.6% |
| Q3 FY2018 | Sep 30, 2018 | $36.43M | +44.3% |
| Q2 FY2018 | Jun 30, 2018 | $44.73M | +93.5% |
| Q1 FY2018 | Mar 31, 2018 | $41.32M | +71.6% |
| Q4 FY2017 | Dec 31, 2017 | $34.83M | +68.5% |
| Q3 FY2017 | Sep 30, 2017 | $25.24M | +26.9% |
| Q2 FY2017 | Jun 30, 2017 | $23.12M | – |
| Q1 FY2017 | Mar 31, 2017 | $24.08M | – |
| Q4 FY2016 | Dec 31, 2016 | $20.67M | – |
| Q3 FY2016 | Sep 30, 2016 | $19.89M | – |
See a number that looks wrong?